GleamWall
中文EN

MIRM Mirum Pharmaceuticals, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1759425 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY42.2%
TTM net income YoY-2,082.1%
TTM EPS YoY-1,622.6%
Revenue 3-yr CAGR66.7%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-133.6%
Net margin-134.8%
FCF margin-40.8%
EBITDA margin-129.6%

Returns

ROE-760.0%
ROA-99.8%
ROIC (approx.)—
Asset turnover0.74x

Leverage & solvency

Liabilities / assets105.3%
Debt / equity—
Current ratio2.07x
Interest coverage-78.36x

Cash quality & payout

Operating cash flow / net income0.30x
Accruals ratio-69.8%
Payout ratio—
Capex / revenue0.4%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$185.72M$176.24M$159.88M$148.93M$133.01M$127.78M$111.58M$99.41M
R&D expense$107.93M$90.53M$97.91M$51.11M$42.96M$46.07M$41.04M$44.03M
SG&A expense$88.86M$81.47M$96.33M$74.13M$61.91M$63.29M$57.71M$56.83M
Operating income-$59.75M-$42.54M-$789.47M-$4.57M$2.60M-$4.99M-$15.18M-$24.22M
Interest expense$1.61M$2.62M$3.62M$3.60M$3.61M$3.59M$3.60M$3.58M
Pretax income-$40.23M-$65.54M-$789.68M-$4.96M$2.64M-$5.46M-$13.65M-$24.37M
Income tax$538,000$1.69M$475,000$767,000-$262,000$402,000$1.03M-$576,000
Net income-$40.77M-$67.23M-$790.15M-$5.73M$2.90M-$5.86M-$14.68M-$23.79M
EBITDA-$52.86M-$35.60M-$782.59M$1.51M$8.66M$1.07M-$9.13M-$18.17M
EPS (basic)-0.62-1.06-13.43—0.06-0.12-0.30—
EPS (diluted)-0.87-1.06-13.43—0.05-0.12-0.30—
Weighted avg. shares (diluted)66.05M63.37M58.85M—56.99M49.73M48.89M—
Balance sheet
Cash & equivalents$243.19M$330.73M$324.91M$296.68M$282.02M$228.12M$211.82M$222.50M
Short-term investments$130.50M$107.56M$61.35M$86.64M$93.53M$76.43M$65.85M$57.81M
Receivables$156.35M$145.36M$133.11M$123.33M$107.13M$106.84M$95.85M$78.29M
Inventory$25.49M$25.77M$25.52M$24.89M$24.02M$22.94M$22.42M$22.40M
Current assets$586.63M$636.31M$569.44M$549.68M$530.58M$453.40M$410.82M$392.79M
PP&E, net$3.25M$2.25M$2.41M$1.86M$1.28M$1.18M$1.11M$1.14M
Intangibles$275.65M$247.39M$254.15M$260.92M$231.90M$237.87M$243.84M$249.82M
Total assets$1.03B$1.04B$890.92M$842.81M$785.12M$725.83M$690.25M$670.75M
Current liabilities$283.08M$222.79M$272.82M$205.80M$160.36M$144.80M$127.58M$126.55M
Total liabilities$1.08B$1.06B$648.42M$528.12M$493.07M$470.67M$456.99M$445.11M
Shareholders' equity-$54.19M-$10.42M$242.49M$314.69M$292.05M$255.16M$233.26M$225.64M
Shares outstanding65.21M64.75M60.93M51.90M51.31M50.06M49.45M48.34M
Cash flow statement
Operating cash flow-$4.31M-$44.25M-$228.76M$6.07M$39.68M$12.04M-$1.96M-$5.07M
Capital expenditure$1.30M$23,000$664,000$600,000$187,000$126,000$41,000$20,000
Free cash flow-$5.62M-$44.27M-$229.43M$5.47M$39.49M$11.91M-$2.00M-$5.09M
Investing cash flow-$28.87M-$159.99M-$11.57M$1.01M-$2.23M-$6.60M-$16.13M$641,000
Financing cash flow-$54.34M$211.44M$270.08M$9.00M$16.10M$8.69M$6.36M$5.34M
Depreciation & amortization$6.89M$6.94M$6.87M$6.07M$6.06M$6.06M$6.05M$6.06M
Stock-based compensation$33.31M$30.57M$36.20M$19.03M$18.13M$18.47M$15.80M$13.25M

Free plan shows the latest 8 periods; Pro shows all 33 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.